Key result
Platelet CD62p expression was significantly higher in acute ischemic stroke than in controls (P<0.0001) and was significantly independently suppressed by clopidogrel on day 90 (P=0.0016).
Why the study?
Do antiplatelet therapies suppress platelet CD62p expression in patients after acute ischemic stroke?
Population
87 consecutive patients with acute ischemic stroke, 20 healthy volunteers, and 33 at-risk control subjects
Comparison
Antiplatelet therapies including aspirin… vs Healthy volunteers, at-risk control subjects…
Design
Cohort
Follow-up
90 days
Authors
Loading...
Clopidogrel-associated CD62p suppression at 90 days after ischemic stroke is hypothesis-generating; prospective trials needed before clinical adoption.
Observational (n=140)
Do antiplatelet therapies suppress platelet CD62p expression in patients after acute ischemic stroke?
p-value: p=<0.0001
Clopidogrel demonstrates greater long-term pharmacodynamic potency than aspirin in suppressing platelet activation after acute ischemic stroke.
Yip et al. (2004) conducted an observational in Acute ischemic stroke (n=140). Acute ischemic stroke and antiplatelet therapies (aspirin, clopidogrel) vs. Healthy volunteers, at-risk controls, and warfarin was evaluated on Platelet CD62p expression (p=<0.0001). Platelet CD62p expression was significantly higher in acute ischemic stroke than in controls (P<0.0001) and was significantly independently suppressed by clopidogrel on day 90 (P=0.0016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: